Last reviewed · How we verify
Glibenclamide + Metformin
Glibenclamide stimulates insulin secretion from pancreatic beta cells while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.
Glibenclamide stimulates insulin secretion from pancreatic beta cells while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glibenclamide + Metformin |
|---|---|
| Sponsor | University of Zambia |
| Drug class | Sulfonylurea + Biguanide combination |
| Target | ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial complex I and AMP-activated protein kinase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glibenclamide is a sulfonylurea that binds to ATP-sensitive potassium channels on beta cells, triggering insulin release. Metformin is a biguanide that decreases gluconeogenesis and glycogenolysis in the liver and enhances peripheral glucose uptake and utilization. The combination addresses both insulin deficiency and insulin resistance.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Weight gain
- Lactic acidosis (rare)
- Headache
Key clinical trials
- Diabetes Management for Primary Healthcare Centers. (NA)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis (PHASE2)
- Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus (PHASE4)
- Metformin Compared to Glyburide in Gestational Diabetes (NA)
- Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes (NA)
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glibenclamide + Metformin CI brief — competitive landscape report
- Glibenclamide + Metformin updates RSS · CI watch RSS
- University of Zambia portfolio CI